ATE71303T1 - Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. - Google Patents
Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.Info
- Publication number
- ATE71303T1 ATE71303T1 AT87200035T AT87200035T ATE71303T1 AT E71303 T1 ATE71303 T1 AT E71303T1 AT 87200035 T AT87200035 T AT 87200035T AT 87200035 T AT87200035 T AT 87200035T AT E71303 T1 ATE71303 T1 AT E71303T1
- Authority
- AT
- Austria
- Prior art keywords
- immunogenic
- preparation
- pharmaceutical composition
- composition containing
- detergent
- Prior art date
Links
- 230000001900 immune effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 4
- 229930182558 Sterol Natural products 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003599 detergent Substances 0.000 abstract 2
- 229930182470 glycoside Natural products 0.000 abstract 2
- 150000002338 glycosides Chemical class 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 150000003432 sterols Chemical class 0.000 abstract 2
- 235000003702 sterols Nutrition 0.000 abstract 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8600066 | 1986-01-14 | ||
| EP87200035A EP0231039B1 (de) | 1986-01-14 | 1987-01-13 | Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE71303T1 true ATE71303T1 (de) | 1992-01-15 |
Family
ID=19847414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT87200035T ATE71303T1 (de) | 1986-01-14 | 1987-01-13 | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4900549A (de) |
| EP (1) | EP0231039B1 (de) |
| JP (2) | JP2502558B2 (de) |
| AT (1) | ATE71303T1 (de) |
| CA (1) | CA1279012C (de) |
| DE (1) | DE3775783D1 (de) |
| DK (1) | DK166762B1 (de) |
| ES (1) | ES2039229T3 (de) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| ATE71303T1 (de) * | 1986-01-14 | 1992-01-15 | Nederlanden Staat | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
| US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
| EP0318081B1 (de) * | 1987-11-27 | 1991-07-24 | Akzo N.V. | Stabilisierung von Antikörpern |
| US6291228B1 (en) | 1988-08-03 | 2001-09-18 | Vericore Limited | Vaccine |
| NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| GB8919819D0 (en) * | 1989-09-01 | 1989-10-18 | Coopers Animal Health | Complexes having adjuvant activity |
| US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| US5443832A (en) * | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
| NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
| SE502569C2 (sv) * | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
| WO1993020802A1 (en) * | 1992-04-09 | 1993-10-28 | Northwestern University | Acoustically reflective liposomes and methods to make and use the same |
| DE4220653A1 (de) * | 1992-06-26 | 1994-01-13 | Boehringer Mannheim Gmbh | Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside |
| EP0688206B1 (de) * | 1993-02-26 | 2000-05-03 | Fountain Pharmaceuticals, Inc. | Abgabesystem für impfstoffe und lagerstabile vorstufenlösung zur nachträglichen verkapselung von aktivstoffen |
| AUPM500494A0 (en) * | 1994-04-12 | 1994-05-05 | Minister For Agriculture & Rural Affairs For The State Of New South Wales, The | Composition for use in increasing mucosal immunity |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| GB9618119D0 (en) * | 1996-08-30 | 1996-10-09 | Univ Southampton | Adjuvants for use in vaccines |
| US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
| US20070059327A2 (en) * | 1998-01-15 | 2007-03-15 | Wyeth | Streptococcus equi compositions and methods of use |
| GB2348203B (en) | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| AU783344B2 (en) | 1999-02-17 | 2005-10-20 | Csl Limited | Immunogenic complexes and methods relating thereto |
| US6790950B2 (en) | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| EP2281834B1 (de) | 1999-04-09 | 2015-03-04 | Zoetis P&U LLC | Attenuiertes Bakterium der Familie Pasteurellaceae welches ein mutiertes Virulenzgen aufweist |
| AU2001256957B2 (en) | 2000-03-17 | 2005-08-25 | Pharmacia & Upjohn Company Llc | Salmonella vaccine materials and methods |
| US6764823B2 (en) | 2000-04-06 | 2004-07-20 | Pharmacia & Upjohn Company | Antimicrobial methods and materials |
| US7323174B1 (en) | 2000-06-12 | 2008-01-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulation of immune response and methods based thereon |
| CU23002A1 (es) * | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
| CA2327950A1 (en) * | 2000-12-08 | 2002-06-08 | Groupe Minutia Inc. | Grain refining agent for cast aluminum or magnesium products |
| US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| GB0112126D0 (en) | 2001-05-18 | 2001-07-11 | Allergene Inc | Composition |
| IL145926A0 (en) * | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
| US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
| SE0202110D0 (sv) * | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| US7491395B2 (en) | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| AU2003296592A1 (en) * | 2002-11-20 | 2004-06-15 | Crucell Holland B.V. | Antigen-complexes |
| IL155136A0 (en) | 2003-02-10 | 2003-10-31 | Enzymotec Ltd | A composition for reducing blood cholesterol and triglycerides |
| US20060233863A1 (en) | 2003-02-10 | 2006-10-19 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy |
| EP1447080A1 (de) * | 2003-02-13 | 2004-08-18 | Bestewil Holding B.V. | Methode zur Herstellung von Virosomen-artigen Partikeln |
| SE0300795D0 (sv) * | 2003-03-24 | 2003-03-24 | Isconova Ab | Composition comprising iscom particles and live micro-organisms |
| TWI329130B (en) | 2003-06-19 | 2010-08-21 | Bestewil Holding Bv | Functionally reconstituted viral membranes containing adjuvant |
| US9023366B2 (en) | 2003-07-01 | 2015-05-05 | The Royal Veterinary College | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD) |
| GB0315323D0 (en) | 2003-07-01 | 2003-08-06 | Royal Veterinary College | Vaccine composition |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| WO2007026190A2 (en) | 2004-07-18 | 2007-03-08 | Csl Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| WO2006016357A1 (en) * | 2004-08-09 | 2006-02-16 | Enzymotec Ltd. | Food products for diabetics |
| BRPI0513461A2 (pt) | 2004-08-10 | 2011-05-10 | Enzymotec Ltd | mÉtodos de tratamento requerendo fito-ingredientes |
| BRPI0606481A2 (pt) | 2005-01-20 | 2009-06-30 | Isconova Ab | composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina |
| WO2006133879A2 (en) | 2005-06-16 | 2006-12-21 | Universiteit Gent | Vaccines for immunization against helicobacter |
| US20100129288A1 (en) * | 2005-06-28 | 2010-05-27 | Elior Peles | Gliomedin, Fragments Thereof and Methods of Using Same |
| EP2292250A1 (de) | 2005-07-28 | 2011-03-09 | Pfizer Products Inc. | Verfahren zur Verabreichung eines Impfstoffes, neue feline Caliciviren und Behandlungen zur Impfung von Tieren gegen felinen Parvovirus und felinen Herpesvirus |
| EP1764369A1 (de) | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
| KR20110126726A (ko) | 2005-10-07 | 2011-11-23 | 화이자 프로덕츠 인코포레이티드 | 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법 |
| NZ577855A (en) | 2006-12-27 | 2012-07-27 | Pfizer Prod Inc | Vaccination schedule to prevent canine disease |
| US20100150924A1 (en) * | 2007-05-22 | 2010-06-17 | Elior Peles | Regulation of myelination by nectin-like (necl) molecules |
| JP2010038051A (ja) | 2008-08-06 | 2010-02-18 | Denso Corp | 車載動力発生装置のトルク制御装置 |
| MX375965B (es) | 2010-05-14 | 2025-03-07 | Baxalta Inc | Genes ospa quimericos, proteinas, y metodos para usar los mismos. |
| NZ605147A (en) * | 2010-06-24 | 2014-12-24 | Genentech Inc | Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations |
| WO2012010290A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| WO2012010291A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| EP2635593B1 (de) | 2010-11-05 | 2016-09-14 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Impfstoffe zur verhinderung von meningokokken-infektionen |
| EP2462950A1 (de) | 2010-12-08 | 2012-06-13 | Neovacs | Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung |
| BR112013014302A2 (pt) | 2010-12-08 | 2016-09-20 | Neovacs | vacina fortemente inativada e ainda altamente imunogênica e processo de fabricação da mesma |
| EP2691111B1 (de) | 2011-03-31 | 2017-09-20 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Verwendung von bacteriome aus blut oder gewebe für vorhersage, diagnose und prävention von stoffwechselkrankheiten und ihre kardiovaskulären komplikationen |
| EP2508197A1 (de) | 2011-04-07 | 2012-10-10 | Neovacs | Verfahren zur Behandlung IFN-alpha-assoziierter Erkrankungen |
| CA2832260C (en) | 2011-04-07 | 2021-06-22 | Neovacs | Method for treating ifnalpha related conditions |
| DK2750683T4 (da) | 2011-10-03 | 2021-04-12 | Croda Int Plc | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser |
| GB201200259D0 (en) | 2012-01-09 | 2012-02-22 | Ohlin Per M | Novel therapies |
| JP2015524802A (ja) | 2012-07-27 | 2015-08-27 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | キメラｏｓｐａ分子を含む組成物およびその使用方法 |
| EP2949339A1 (de) | 2014-05-29 | 2015-12-02 | Ospedale San Raffaele S.r.l. | Agonisten von CD1c-abhängigen T Zellen und Verwendungen davon |
| EP3613764A1 (de) | 2014-10-15 | 2020-02-26 | Xenothera | Zusammensetzung mit verminderter immunogenität |
| IL303336B2 (en) | 2015-09-03 | 2025-08-01 | Novavax Inc | Vaccine compositions having improved stability and immunogenicity |
| ES3028362T3 (en) | 2017-07-24 | 2025-06-19 | Novavax Inc | Methods and compositions for treating respiratory disease |
| CN120227451A (zh) | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| EP3922255A1 (de) | 2020-06-10 | 2021-12-15 | Prokarium Limited | Krebstherapie |
| EP4124342A1 (de) | 2021-07-28 | 2023-02-01 | Prokarium Limited | Krebstherapie mit lebenden attenuierten bakterien |
| GB2622559A (en) | 2022-05-10 | 2024-03-27 | Johan Frostegaard | Compositions, methods and uses |
| GB202215134D0 (en) | 2022-10-13 | 2022-11-30 | Prokarium Ltd | Composition |
| GB202215576D0 (en) | 2022-10-21 | 2022-12-07 | Prokarium Ltd | Circuit |
| WO2025068413A1 (en) | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 18 variants |
| WO2025068401A1 (en) | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 15 variant |
| WO2025109155A1 (en) | 2023-11-24 | 2025-05-30 | Prokarium Limited | Interleukin variant |
| KR20250155284A (ko) * | 2024-04-23 | 2025-10-30 | (주)아모레퍼시픽 | 미셀을 이용한 유효성분의 봉입 및 안정성 개선 방법 |
| GB202405780D0 (en) | 2024-04-24 | 2024-06-05 | Prokarium Ltd | Vacuole escape |
| WO2025224251A1 (en) | 2024-04-24 | 2025-10-30 | Prokarium Limited | Modified microorganisms |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1502774A (en) * | 1974-06-25 | 1978-03-01 | Nat Res Dev | Immunological preparations |
| US4196191A (en) * | 1975-09-29 | 1980-04-01 | Burroughs Wellcome Co. | Biological preparations |
| US4201767A (en) * | 1978-11-08 | 1980-05-06 | Merck & Co., Inc. | Viral liposome particle |
| AU534679B2 (en) * | 1979-03-15 | 1984-02-09 | Commonwealth Scientific And Industrial Research Organisation | Steroid immunogens |
| DE3068743D1 (en) * | 1980-01-16 | 1984-08-30 | Weder Hans G | Process and dialysis-installation for the preparation of bilayer-vesicles and their use |
| US4439199A (en) * | 1980-02-19 | 1984-03-27 | Alza Corporation | Method for administering immunopotentiator |
| DE3014189A1 (de) * | 1980-04-14 | 1981-10-15 | Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg | Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren |
| EP0047480B1 (de) * | 1980-09-05 | 1986-02-05 | Institut Armand Frappier | Bildung eines Immunosoms, das ausschliesslich aus Virusantigenen, die auf einer künstlichen Membran rekonstruiert sind, hergestellt wird |
| US4386066A (en) * | 1981-08-20 | 1983-05-31 | Merck & Co., Inc. | Immunogenic complex from N. gonorrhoeae |
| SE8205892D0 (sv) * | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| EP0142192A1 (de) * | 1983-10-22 | 1985-05-22 | Akzo N.V. | Herstellung von Immunogenen bestehend aus an Glykosid enthaltenden Trägern gebundenen antigenen Determinanten |
| SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| ATE71303T1 (de) * | 1986-01-14 | 1992-01-15 | Nederlanden Staat | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
| US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
-
1987
- 1987-01-13 AT AT87200035T patent/ATE71303T1/de not_active IP Right Cessation
- 1987-01-13 DE DE8787200035T patent/DE3775783D1/de not_active Expired - Lifetime
- 1987-01-13 DK DK015087A patent/DK166762B1/da not_active IP Right Cessation
- 1987-01-13 EP EP87200035A patent/EP0231039B1/de not_active Expired - Lifetime
- 1987-01-13 ES ES198787200035T patent/ES2039229T3/es not_active Expired - Lifetime
- 1987-01-14 CA CA000527289A patent/CA1279012C/en not_active Expired - Lifetime
- 1987-01-14 US US07/003,070 patent/US4900549A/en not_active Expired - Lifetime
- 1987-01-14 JP JP62007384A patent/JP2502558B2/ja not_active Expired - Lifetime
-
1995
- 1995-11-28 JP JP7309056A patent/JP2703528B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK166762B1 (da) | 1993-07-12 |
| US4900549A (en) | 1990-02-13 |
| EP0231039B1 (de) | 1992-01-08 |
| JP2502558B2 (ja) | 1996-05-29 |
| JP2703528B2 (ja) | 1998-01-26 |
| DK15087D0 (da) | 1987-01-13 |
| EP0231039A1 (de) | 1987-08-05 |
| CA1279012C (en) | 1991-01-15 |
| DE3775783D1 (de) | 1992-02-20 |
| JPH08208513A (ja) | 1996-08-13 |
| DK15087A (da) | 1987-07-15 |
| ES2039229T3 (es) | 1993-09-16 |
| JPS632933A (ja) | 1988-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE71303T1 (de) | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. | |
| DE68921389T2 (de) | Influenzaimpfstoff und Adjuvanten. | |
| DE69010574T2 (de) | Hilfsmittelformulierung die eine Emulsion mit submikronischen Oeltropfen enthält. | |
| KR940001373B1 (ko) | 인플루엔자 백신의 제조방법 | |
| CA2086831C (en) | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them | |
| AU632067B2 (en) | Matrix with immunomodulating activity | |
| DE69131709T2 (de) | Liposomen enthaltende impfstoffzusammensetzungen | |
| DE69605296T2 (de) | Impfstoffe die ein saponin und ein sterol enthalten | |
| ATE71834T1 (de) | Liposomzubereitung und ihre herstellung. | |
| JP2002522397A (ja) | 他の界面活性剤を含有しない、ステロールとサポニンから成るｉｓｃｏｍを含むワクチン | |
| DK0524968T3 (da) | Heterovesikulære lipidvesikler | |
| US4148876A (en) | Biological preparations | |
| ZA834998B (en) | Liquid active ingredient concentrates for preparation of microemulsions | |
| ES2085920T3 (es) | Liposomas dirigidos y metodos de acoplamiento liposoma-proteina. | |
| KR950700083A (ko) | 경구용 백신(oral vaccine) | |
| DE68919173T2 (de) | Affinitätsassoziierter Impfstoff. | |
| GB1564500A (en) | Biological preparations | |
| ES2234152T3 (es) | Vectores de antigenos en forma de vesiculas multilamelares. | |
| DE69505236T2 (de) | Liposomen und deren verwendung insbesondere zur herstellung immunomodulatorischer mittel | |
| Freitas et al. | The Use of Liposomes as Snake Venom Vehicles. Application in Protective Immunization | |
| DE69710476T2 (de) | Alkaloidglykoside zur verwendung als arzneimittel | |
| KR0178422B1 (ko) | 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
| KR0173366B1 (ko) | B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
| DK302987A (da) | Fremgangsmaade til fremstilling af et immunogent kompleks | |
| JP2004161781A (ja) | 経口ワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |